Norway· NO-ID_CFD83876-476D-4A84-868A-2538A8B2AC66
Parsabiv
A etelcalcetide product containing etelcalcetide, registered in Norway by Amgen Europe B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Etelcalcetide is registered in 14 of 19 countries.
Countries holding a registration under ATC H05BX04 (etelcalcetide), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Etelcalcetide · ATC H05BX04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Etelcalcetide
- Manufacturer
- Amgen Europe B.V.
- Country
- Norway (NO)
- ATC code
- H05BX04
- ATC class
- Etelcalcetide
- Defined daily dose
- 2.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_varenummer4351626 x 0.5NOK 1105.7
- no_merkevare_idID_CFD83876-476D-4A84-868A-2538A8B2AC66
- gtin8715131015343
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for etelcalcetide.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etelcalcetide · interactions on record
20 records
- 19 severe
- 1 moderate
Most severe, free to view
- FurosemideC03CA01severe
- BumetanideC03CA02severe
- TorasemideC03CA04severe
- Etacrynic acidC03CC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Etelcalcetide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandParsabiv 10.0 mg, InjektionslösungAmgen Switzerland AG
- CzechiaPARSABIVAmgen Europe B.V., Breda
- SpainPARSABIV 10 MG SOLUCION INYECTABLEAmgen Europe B.V.
- FinlandParsabivAmgen Europe B.V.
- FrancePARSABIV 10 mg, solution injectableAMGEN EUROPE
- United KingdomParsabiv 10mg/2ml solution for injection vialsAmgen Ltd
- IrelandParsabiv 10 mg solution for injectionAmgen Europe B.V.,
- IcelandParsabivAmgen Europe B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Iceland · Parsabiv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a8e3f62b-b1c7-44db-89a8-598b1dd27b79 GET /v1/drugs/a8e3f62b-b1c7-44db-89a8-598b1dd27b79?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Etelkalsetid",
"merkevare_id": "ID_CFD83876-476D-4A84-868A-2538A8B2AC66",
"name_form_strength": "Parsabiv inj, oppl 2,5 mg/0,5 ml",
"prescription_group": "C"
}See everything about etelcalcetide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.